A randomized, placebo-controlled Phase 1 clinical trial designed to assess the safety, tolerability and efficacy of BRC-002 when taken orally to address the symptoms of Complex Regional Pain Syndrome(CRPS)
Latest Information Update: 10 Oct 2024
At a glance
- Drugs BRC 002 (Primary)
- Indications Complex regional pain syndromes
- Focus Adverse reactions
- 10 Oct 2024 New trial record
- 03 Oct 2024 According to Biopharmaceutical Research Company, announced today that the first dose in an investigator-initiated Phase 1 clinical trial of BRC-002 for Complex Regional Pain Syndrome (CRPS) has been administered.